Abstract

Compounding Pharmacies: Before and After an Inspection

Author(s): Kulkarni Darshan, Ricketts Samantha

Issue: Sep/Oct 2013 - Volume 17, Number 5

Page(s): 358-362

Download in electronic PDF format for $75

Abstract

Recent events have directed the U.S. Food and Drug Administration’s attention to compounding pharmacies and have increased the frequency and vigorousness of pharmacy inspections. It is critical for compounding pharmacists to be prepared for such inspections and to understand their responsibilities after an inspection is over.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Mar/Apr 2017 Pg. 95-102	U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Author(s): Yoch Doug
Jul/Aug 2016 Pg. 351 View Sample	Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Author(s): Allen Loyd V Jr
Sep/Oct 2018 Pg. 401-404	Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1 Author(s): Martin Matt
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr
Sep/Oct 2013 Pg. 358-362	Compounding Pharmacies: Before and After an Inspection Author(s): Kulkarni Darshan, Ricketts Samantha
Sep/Oct 2020 Pg. 371-379	Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance Author(s): Greeson Nicole MH, Mixon William, Allan W Chris
Sep/Oct 2017 Pg. 373-380	Documentation: Records and Reports Author(s): Akers Michael J
Jul/Aug 2015 Pg. 303-305	U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Author(s): Miller David G
Jan/Feb 2023 Pg. 22-23	The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Author(s): Brunner Scott
Sep/Oct 2013 Pg. 356	PreScription: GMPs vs. GCPs: Manufacturing and Compounding Definitions Author(s): Allen Loyd V Jr
Nov/Dec 2015 Pg. 453-463	Applying Quality of Design Concepts to Pharmacy Compounding Author(s): Timko Robert J
Mar/Apr 2014 Pg. 101-111	Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective Author(s): Timko Robert J, Crooker Philip EM
Jan/Feb 2019 Pg. 32-33	U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Nov/Dec 2015 Pg. 487-488	U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Author(s): Allen Loyd V Jr
Sep/Oct 2018 Pg. 387-398	Compounding Enclosures: Ensuring Safety During the Preparation of Sterile and Nonsterile Formulations Author(s): Ashe Krystina, Baskett Dustin
Mar/Apr 2020 Pg. 92	PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>,<797>, and <825>: Part 1 Author(s): Allen Loyd V Jr
Sep/Oct 2015 Pg. 389-390	Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Author(s): Allen Loyd V Jr
Jan/Feb 2018 Pg. 7-16	Certification, Accreditation, and Credentialing for 503A Compounding Pharmacies Author(s): Pritchett Jon, McCrory Gary, Kraemer Cheri, Jensen Brenda, Allen Loyd V Jr
Jan/Feb 2017 Pg. 4	PreScription: Compounding Pharmacy Issues for 2017 Author(s): Allen Loyd V Jr
May/Jun 2014 Pg. 208	The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Author(s): Miller David G